Recent FDA and HHS Actions Spur Development of U.S. Zika Test Market

For further information regarding the U.S. blood screening diagnostics and global infectious disease diagnostics markets, Kalorama Information offers the recent market research reports United States Market for In Vitro Diagnostic Tests and The World Market for Infectious Disease Diagnostic Tests.

Investigational and emergency authorized Zika virus diagnostics are expected to find rising demand from U.S. customers following the recent expansion of a U.S. Food and Drug Administration (FDA) recommendation, and will be joined in U.S. healthcare surveillance by rapid tests currently in development under U.S. Department of Health and Human Services (HHS) financial assistance.

IVD Market Exceeds $60BN: New Report

The global IVD market is currently 60.5 billion dollars, according to Kalorama Information's recently released report on in vitro diagnostic (IVD) test markets.  Kalorama published our tenth edition of its study, The World Market for In Vitro Diagnostic Tests, available at   After exhaustive study, the report says IVD will grow but in a complex pattern that involves challenges to growth in traditional categories and reliable large markets combined with opportunities in novel tests and growth nations.

Envisioning an Essential Diagnostics List (EDL) and Its IVD Market Impact

Kalorama Information offers relevant market research in the areas of molecular point-of-care (POC) diagnostics, traditional POC diagnostics, and physician office laboratory (POL) test markets. Market information in this post was drawn from the associated reports.

In a recent article of the New England Journal of Medicine (NEJM), health and medical experts convincingly argued for the establishment of an Essential Diagnostics List (EDL) modeled on the existing Essential Medicines List (EML). Effective use of essential medicines, including stewardship of distributed antibiotics, would be encouraged through the equal availability of diagnostics. In this post, Kalorama Information identified several core EDL test categories outlined by the NEJM article’s authors that are represented by currently marketed physician office laboratory (POL) and point-of-care (POC) diagnostics. While the potential to address future EDL-driven markets through existing IVD products exists, significant cost improvements will be necessary.

U.S. Hospitals Leverage New IVD Products in the Fight Against Critical Inpatient Infections (AACC 2016)

This blog post continues Kalorama Information’s coverage of the 2016 AACC Annual Meeting in Philadelphia. Additional coverage of trends in the U.S. IVD market as well as segment market sizes and projections are available with Kalorama’s recent market research report.

With mounting cost pressures on U.S. labs and the growing accountability of diagnostics in critical patient episodes, vendors at the 2016 Annual Meeting of the American Association of Clinical Chemistry (AACC) emphasized solutions that addressed lab efficiency and mitigation of added healthcare costs. Test and workflow automation solutions at the AACC expo in Philadelphia were reviewed in a previous blog post as relevant tools for improving lab cost efficiency. Diagnostics are also crucial tools for hospitals to avoid payment penalties resulting from poor performance or non-compliance with care standards related to hospital-acquired infections (HAIs) and sepsis.

At AACC 2016, Lab Testing Set to Move Forward Through Test and Workflow Automation

Proceedings at AACC’s Annual Meeting were notably charged in one way: the proliferation of coffee stands at vendor booths across the expo floor. Vendor demonstrations matched pace as several IVD vendors put their automated testing solutions front and center for speedy sample management and reduced turnaround times. While media attention gravitated to Theranos’ Monday presentation, attendees at Philadelphia were preoccupied with addressing the present challenges of laboratory medicine.


Subscribe to Kalorama Information Home RSS